Oluyemi Okupe Sells 29,277 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 29,277 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $29.95, for a total transaction of $876,846.15. Following the completion of the transaction, the chief financial officer owned 236,527 shares of the company’s stock, valued at $7,083,983.65. This trade represents a 11.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.82, for a total value of $354,860.66.
• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total value of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.

Hims & Hers Health Trading Down 6.6%

NYSE:HIMS traded down $2.00 on Wednesday, hitting $28.43. 11,816,307 shares of the stock were exchanged, compared to its average volume of 24,193,828. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30. The stock has a market capitalization of $6.63 billion, a price-to-earnings ratio of -45.13 and a beta of 2.42. The company’s 50-day moving average price is $29.87 and its 200 day moving average price is $27.88.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same quarter in the prior year, the company earned $0.17 earnings per share. The company’s quarterly revenue was up 38.2% on a year-over-year basis. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Several firms, including Kaplan Fox, Faruqi & Faruqi, Rosen Law Firm and others, reminded investors that November 2, 2026 is the deadline to seek lead-plaintiff status in a federal securities class action covering purchases of HIMS securities from August 4, 2025, through July 29, 2026. Kaplan Fox investor notice
• Negative Sentiment: The lawsuit alleges that Hims & Hers and certain executives made material misstatements or omissions regarding allegedly deceptive and unlawful privacy and billing practices. The claims reportedly stem in part from allegations in a Federal Trade Commission complaint. Hagens Berman lawsuit notice
• Negative Sentiment: The concentrated publicity increases reputational, regulatory and potential litigation-cost concerns for HIMS. Investors should note that the allegations have not been proven, and the notices do not indicate the likely damages, outcome or financial impact of the case.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HIMS. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Morgan Stanley boosted their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Citigroup lowered their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Bank of America lifted their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. began coverage on shares of Hims & Hers Health in a report on Friday, September 11th. They issued a “neutral” rating and a $32.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $32.43.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HIMS. Bienville Capital Management LLC bought a new stake in shares of Hims & Hers Health during the second quarter worth $27,242,000. Engineers Gate Manager LP acquired a new stake in shares of Hims & Hers Health in the 2nd quarter valued at about $232,000. Integrated Wealth Concepts LLC bought a new stake in shares of Hims & Hers Health in the second quarter valued at about $147,000. Baird Financial Group Inc. lifted its holdings in shares of Hims & Hers Health by 384.6% in the second quarter. Baird Financial Group Inc. now owns 65,575 shares of the company’s stock valued at $2,273,000 after purchasing an additional 52,043 shares in the last quarter. Finally, Nykredit A S acquired a new position in shares of Hims & Hers Health during the second quarter worth about $222,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.